Skip to main content
NCBI home page
Emerging Infectious Diseases logoLink to Emerging Infectious Diseases
. 1998 Apr-Jun;4(2):263–268. doi: 10.3201/eid0402.980213

Campylobacter jejuni strains from patients with Guillain-Barré syndrome.

B M Allos 1, F T Lippy 1, A Carlsen 1, R G Washburn 1, M J Blaser 1
PMCID: PMC2640125  PMID: 9621196

Abstract

Guillain-Barré syndrome (GBS), an acute demyelinating peripheral neuropathy, may be triggered by an acute infectious illness; infection with Campylobacter jejuni is the most frequently reported antecedent event. In Japan, O:19 is the most common serotype among GBS-associated C. jejuni strains. To determine whether serotype O:19 occurs among GBS-associated strains in the United States and Europe, we serotyped seven such strains and found that two (29%) of seven GBS-associated strains from patients in the United States and Germany were serotype O:19. To determine whether GBS-associated strains may be resistant to killing by normal human serum (NHS), we studied the serum susceptibility of 17 GBS- and 27 enteritis-associated strains (including many O:19 and non-O:19 strains) using C. jejuni antibody positive (pool 1) or negative (pool 2) human serum. Using pool 1 serum we found that one (6%) of 18 serotype O:19 strains compared with 11 (42%) of 26 non-O:19 strains were killed; results using pool 2 serum were nearly identical. Finally, 8 O:19 and 8 non-O:19 strains were not significantly different in their ability to bind complement component C3. Serotype O:19 C. jejuni strains were overrepresented among GBS-associated strains in the United States and Germany and were significantly more serum-resistant than non-O:19 strains. The mechanism of this resistance appears unrelated to C3 binding.

Full Text

The Full Text of this article is available as a PDF (34.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allos B. M., Blaser M. J. Campylobacter jejuni infection and the Guillain-Barre syndrome: mechanisms and implications. Zentralbl Bakteriol. 1994 Nov;281(4):544–548. doi: 10.1016/s0934-8840(11)80343-9. [DOI] [PubMed] [Google Scholar]
  2. Allos B. M. Campylobacter jejuni infection as a cause of the Guillain-Barré syndrome. Infect Dis Clin North Am. 1998 Mar;12(1):173–184. doi: 10.1016/s0891-5520(05)70416-5. [DOI] [PubMed] [Google Scholar]
  3. Blaser M. J., Perez G. P., Smith P. F., Patton C., Tenover F. C., Lastovica A. J., Wang W. I. Extraintestinal Campylobacter jejuni and Campylobacter coli infections: host factors and strain characteristics. J Infect Dis. 1986 Mar;153(3):552–559. doi: 10.1093/infdis/153.3.552. [DOI] [PubMed] [Google Scholar]
  4. Blaser M. J., Smith P. F., Hopkins J. A., Heinzer I., Bryner J. H., Wang W. L. Pathogenesis of Campylobacter fetus infections: serum resistance associated with high-molecular-weight surface proteins. J Infect Dis. 1987 Apr;155(4):696–706. doi: 10.1093/infdis/155.4.696. [DOI] [PubMed] [Google Scholar]
  5. Blaser M. J., Smith P. F., Kohler P. F. Susceptibility of Campylobacter isolates to the bactericidal activity of human serum. J Infect Dis. 1985 Feb;151(2):227–235. doi: 10.1093/infdis/151.2.227. [DOI] [PubMed] [Google Scholar]
  6. Blaser M. J., Smith P. F., Repine J. E., Joiner K. A. Pathogenesis of Campylobacter fetus infections. Failure of encapsulated Campylobacter fetus to bind C3b explains serum and phagocytosis resistance. J Clin Invest. 1988 May;81(5):1434–1444. doi: 10.1172/JCI113474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fujimoto S., Allos B. M., Misawa N., Patton C. M., Blaser M. J. Restriction fragment length polymorphism analysis and random amplified polymorphic DNA analysis of Campylobacter jejuni strains isolated from patients with Guillain-Barré syndrome. J Infect Dis. 1997 Oct;176(4):1105–1108. doi: 10.1086/516522. [DOI] [PubMed] [Google Scholar]
  8. Fujimoto S., Yuki N., Itoh T., Amako K. Specific serotype of Campylobacter jejuni associated with Guillain-Barré syndrome. J Infect Dis. 1992 Jan;165(1):183–183. doi: 10.1093/infdis/165.1.183. [DOI] [PubMed] [Google Scholar]
  9. Gonzalez-Valencia G., Perez-Perez G. I., Washburn R. G., Blaser M. J. Susceptibility of Helicobacter pylori to the bactericidal activity of human serum. Helicobacter. 1996 Mar;1(1):28–33. doi: 10.1111/j.1523-5378.1996.tb00005.x. [DOI] [PubMed] [Google Scholar]
  10. Hillert J., Osterman P. O., Olerup O. No association with HLA-DR, -DQ or -DP alleles in Guillain-Barré syndrome. J Neuroimmunol. 1991 Jan;31(1):67–72. doi: 10.1016/0165-5728(91)90088-o. [DOI] [PubMed] [Google Scholar]
  11. Ho T. W., Mishu B., Li C. Y., Gao C. Y., Cornblath D. R., Griffin J. W., Asbury A. K., Blaser M. J., McKhann G. M. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995 Jun;118(Pt 3):597–605. doi: 10.1093/brain/118.3.597. [DOI] [PubMed] [Google Scholar]
  12. Kuroki S., Saida T., Nukina M., Haruta T., Yoshioka M., Kobayashi Y., Nakanishi H. Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues. Ann Neurol. 1993 Mar;33(3):243–247. doi: 10.1002/ana.410330304. [DOI] [PubMed] [Google Scholar]
  13. Lastovica A. J., Goddard E. A., Argent A. C. Guillain-Barré syndrome in South Africa associated with Campylobacter jejuni O:41 strains. J Infect Dis. 1997 Dec;176 (Suppl 2):S139–S143. doi: 10.1086/513796. [DOI] [PubMed] [Google Scholar]
  14. Lior H., Woodward D. L., Edgar J. A., Laroche L. J., Gill P. Serotyping of Campylobacter jejuni by slide agglutination based on heat-labile antigenic factors. J Clin Microbiol. 1982 May;15(5):761–768. doi: 10.1128/jcm.15.5.761-768.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mishu B., Ilyas A. A., Koski C. L., Vriesendorp F., Cook S. D., Mithen F. A., Blaser M. J. Serologic evidence of previous Campylobacter jejuni infection in patients with the Guillain-Barré syndrome. Ann Intern Med. 1993 Jun 15;118(12):947–953. doi: 10.7326/0003-4819-118-12-199306150-00006. [DOI] [PubMed] [Google Scholar]
  16. Patton C. M., Nicholson M. A., Ostroff S. M., Ries A. A., Wachsmuth I. K., Tauxe R. V. Common somatic O and heat-labile serotypes among Campylobacter strains from sporadic infections in the United States. J Clin Microbiol. 1993 Jun;31(6):1525–1530. doi: 10.1128/jcm.31.6.1525-1530.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rees J. H., Soudain S. E., Gregson N. A., Hughes R. A. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med. 1995 Nov 23;333(21):1374–1379. doi: 10.1056/NEJM199511233332102. [DOI] [PubMed] [Google Scholar]
  18. Rees J. H., Vaughan R. W., Kondeatis E., Hughes R. A. HLA-class II alleles in Guillain-Barré syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection. J Neuroimmunol. 1995 Oct;62(1):53–57. doi: 10.1016/0165-5728(95)00102-8. [DOI] [PubMed] [Google Scholar]
  19. Winer J. B., Briggs D., Welsh K., Hughes R. A. HLA antigens in the Guillain-Barré syndrome. J Neuroimmunol. 1988 Apr;18(1):13–16. doi: 10.1016/0165-5728(88)90130-0. [DOI] [PubMed] [Google Scholar]
  20. Winer J. B., Hughes R. A., Anderson M. J., Jones D. M., Kangro H., Watkins R. P. A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry. 1988 May;51(5):613–618. doi: 10.1136/jnnp.51.5.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Yuki N., Sato S., Fujimoto S., Yamada S., Tsujino Y., Kinoshita A., Itoh T. Serotype of Campylobacter jejuni, HLA, and the Guillain-Barré syndrome. Muscle Nerve. 1992 Aug;15(8):968–969. [PubMed] [Google Scholar]
  22. Yuki N., Taki T., Takahashi M., Saito K., Yoshino H., Tai T., Handa S., Miyatake T. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol. 1994 Nov;36(5):791–793. doi: 10.1002/ana.410360517. [DOI] [PubMed] [Google Scholar]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention

RESOURCES